A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications

Detalhes bibliográficos
Autor(a) principal: Varghese, Resia
Data de Publicação: 2023
Outros Autores: Gopal Krishnamoorthy, Sadagoban, Abdalla, Hassan Elrufae Hassan, Baiju, Aiswarya, Borra, Swathi Swaroopa
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Pharmaceutical Sciences
Texto Completo: https://www.revistas.usp.br/bjps/article/view/207824
Resumo: Fenofibrate is a peroxisome-proliferator-activator α agonist and it is a widely used drug for hyperlipidemia since its approval in 2004. So, in this review we are focusing on the effect of fenofibric acid’s mechanism to alleviate type 1 diabetic micro vascular complications like diabetic retinopathy, diabetic cardiomyopathy in animal models, since the drug is safe, efficacious and more economical when compared with the currently available treatment strategies for juvenile diabetic complications and also a profound observation is needed due to the rarity of research in these therapeutic areas. Important preclinical animal studies published from January 2001 to June 2020 were recognised from databases like PubMed and Cochrane central register of controlled trials. Reviewers screened the articles based on the selection criteria and risk of bias was determined using Systematic Review Centre for Laboratory animal Experimentation risk of bias tool for animal studies. Our literature search yielded a total of 5 studies and after pooling up the data from the 5 preclinical studies, we found that Fenofibrate have the efficacy to prevent type 1 diabetic complications, chiefly diabetic retinopathy and those mechanisms are dependent on peroxisome-proliferator-activator and fibroblast growth factor-21 pathways. Fenofibrate is a well safe and moreover, cost effective medication in preventing type 1 diabetic micro vascular complications especially diabetic retinopathy and also in maintaining the glucose homeostasis in apart from its anti-dyslipidemic effect.
id USP-31_3aa814150cbbf6acb7011ee4f16cac4d
oai_identifier_str oai:revistas.usp.br:article/207824
network_acronym_str USP-31
network_name_str Brazilian Journal of Pharmaceutical Sciences
repository_id_str
spelling A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complicationsDiabetic cardiomyopathyDiabetic retinopathyFenofibrateSphingolipidType 1 diabetic microvascular complicationsType 1 Diabetes mellitusFenofibrate is a peroxisome-proliferator-activator α agonist and it is a widely used drug for hyperlipidemia since its approval in 2004. So, in this review we are focusing on the effect of fenofibric acid’s mechanism to alleviate type 1 diabetic micro vascular complications like diabetic retinopathy, diabetic cardiomyopathy in animal models, since the drug is safe, efficacious and more economical when compared with the currently available treatment strategies for juvenile diabetic complications and also a profound observation is needed due to the rarity of research in these therapeutic areas. Important preclinical animal studies published from January 2001 to June 2020 were recognised from databases like PubMed and Cochrane central register of controlled trials. Reviewers screened the articles based on the selection criteria and risk of bias was determined using Systematic Review Centre for Laboratory animal Experimentation risk of bias tool for animal studies. Our literature search yielded a total of 5 studies and after pooling up the data from the 5 preclinical studies, we found that Fenofibrate have the efficacy to prevent type 1 diabetic complications, chiefly diabetic retinopathy and those mechanisms are dependent on peroxisome-proliferator-activator and fibroblast growth factor-21 pathways. Fenofibrate is a well safe and moreover, cost effective medication in preventing type 1 diabetic micro vascular complications especially diabetic retinopathy and also in maintaining the glucose homeostasis in apart from its anti-dyslipidemic effect.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2023-02-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/20782410.1590/s2175-97902022e21332Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)Brazilian Journal of Pharmaceutical Sciences; v. 58 (2022)Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)2175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/207824/197328Copyright (c) 2022 Brazilian Journal of Pharmaceutical Scienceshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessVarghese, ResiaGopal Krishnamoorthy, Sadagoban Abdalla, Hassan Elrufae HassanBaiju, AiswaryaBorra, Swathi Swaroopa2023-08-18T20:02:26Zoai:revistas.usp.br:article/207824Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2023-08-18T20:02:26Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications
title A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications
spellingShingle A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications
Varghese, Resia
Diabetic cardiomyopathy
Diabetic retinopathy
Fenofibrate
Sphingolipid
Type 1 diabetic microvascular complications
Type 1 Diabetes mellitus
title_short A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications
title_full A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications
title_fullStr A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications
title_full_unstemmed A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications
title_sort A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications
author Varghese, Resia
author_facet Varghese, Resia
Gopal Krishnamoorthy, Sadagoban
Abdalla, Hassan Elrufae Hassan
Baiju, Aiswarya
Borra, Swathi Swaroopa
author_role author
author2 Gopal Krishnamoorthy, Sadagoban
Abdalla, Hassan Elrufae Hassan
Baiju, Aiswarya
Borra, Swathi Swaroopa
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Varghese, Resia
Gopal Krishnamoorthy, Sadagoban
Abdalla, Hassan Elrufae Hassan
Baiju, Aiswarya
Borra, Swathi Swaroopa
dc.subject.por.fl_str_mv Diabetic cardiomyopathy
Diabetic retinopathy
Fenofibrate
Sphingolipid
Type 1 diabetic microvascular complications
Type 1 Diabetes mellitus
topic Diabetic cardiomyopathy
Diabetic retinopathy
Fenofibrate
Sphingolipid
Type 1 diabetic microvascular complications
Type 1 Diabetes mellitus
description Fenofibrate is a peroxisome-proliferator-activator α agonist and it is a widely used drug for hyperlipidemia since its approval in 2004. So, in this review we are focusing on the effect of fenofibric acid’s mechanism to alleviate type 1 diabetic micro vascular complications like diabetic retinopathy, diabetic cardiomyopathy in animal models, since the drug is safe, efficacious and more economical when compared with the currently available treatment strategies for juvenile diabetic complications and also a profound observation is needed due to the rarity of research in these therapeutic areas. Important preclinical animal studies published from January 2001 to June 2020 were recognised from databases like PubMed and Cochrane central register of controlled trials. Reviewers screened the articles based on the selection criteria and risk of bias was determined using Systematic Review Centre for Laboratory animal Experimentation risk of bias tool for animal studies. Our literature search yielded a total of 5 studies and after pooling up the data from the 5 preclinical studies, we found that Fenofibrate have the efficacy to prevent type 1 diabetic complications, chiefly diabetic retinopathy and those mechanisms are dependent on peroxisome-proliferator-activator and fibroblast growth factor-21 pathways. Fenofibrate is a well safe and moreover, cost effective medication in preventing type 1 diabetic micro vascular complications especially diabetic retinopathy and also in maintaining the glucose homeostasis in apart from its anti-dyslipidemic effect.
publishDate 2023
dc.date.none.fl_str_mv 2023-02-07
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/bjps/article/view/207824
10.1590/s2175-97902022e21332
url https://www.revistas.usp.br/bjps/article/view/207824
identifier_str_mv 10.1590/s2175-97902022e21332
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/bjps/article/view/207824/197328
dc.rights.driver.fl_str_mv Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
dc.source.none.fl_str_mv Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)
Brazilian Journal of Pharmaceutical Sciences; v. 58 (2022)
Brazilian Journal of Pharmaceutical Sciences; Vol. 58 (2022)
2175-9790
1984-8250
reponame:Brazilian Journal of Pharmaceutical Sciences
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Brazilian Journal of Pharmaceutical Sciences
collection Brazilian Journal of Pharmaceutical Sciences
repository.name.fl_str_mv Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)
repository.mail.fl_str_mv bjps@usp.br||elizabeth.igne@gmail.com
_version_ 1800222917516066816